The median age at initiation decreased by five years, from 62 years in 2018 to 57 years in 2022, then increasing to 60 years in 2023
Starting at a low dose and gradually increasing it, as prescribed, helps minimise these effects
At present, most of the research is based on animal models and in vitro experiments, and a few pharmacological effects have been clinically confirmed, especially the hypoglycemic effect of catalpol has been verified in the endocrine field, catalpol tablets have entered the phase 2 clinical study (CTR20220555) in China, aiming at evaluating the pharmacokinetics, efficacy and safety of catalpol tablets in patients with type 2 diabetes, small molecular monomer drugs have begun to face the clinic with suitable dosage forms
In practical terms, the two-hormone approach is the reason tirzepatide has set new benchmarks for average weight reduction in clinical research and why it has become one of the most requested treatments in modern obesity medicine
%25201.png)
.jpg)
